ClinicalTrials.gg
CompletedNCT01876381Updated Aug 24, 2018Results posted

A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration

A Phase 2 interventional study of OPC-41061 in Chronic Renal Failure, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 5 sites in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-08-24.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Kidney Failure, Chronic with a site in Japan — 1 open to participants now, 3 under way, 2 of them phase 3. Kidney Failure, Chronic · Japan.

Enrollment
19th of 24
26 · median 127
Started
2013
with 6 others
Phase 2
7 of 30
none open now
Registered
16th of 30
by date
Lead sponsor
3 of 30
Otsuka Pharmaceutical Co., Ltd.

Among the 30 studies in Kidney Failure, Chronic with a site in Japan, this one is the 19th largest by enrollment of the 24 interventional ones that give a count, is one of 7 that started in 2013, is one of 7 in phase 2, and was the 16th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

1 of the 30 studies in Kidney Failure, Chronic with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Kidney Failure, Chronic with a site in Japan, or all of them as a file.
02

Study summary

To investigate the safety, pharmacokinetics, pharmacodynamics, and efficacy of OPC-41061 in patients with chronic renal failure undergoing hemodialysis or hemodiafiltration using variables, such as daily urine volume and increase in interval body weights between hemodialysis or hemodiafiltration, in 4-day intermittant administration (excluding the days of hemodialysis or hemodiafiltration) at the dose fixed during the dose-escalation period

03

Conditions studied

  • Chronic Renal Failure
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with chronic renal failure who are undergoing hemodialysis or hemodiafiltration three times a week
  • Subjects between the ages of 20 and 80, inclusive (at time of )
  • Subjects who are inpatients or who can be admitted to the trial site for the duration of the trial period
  • Subjects who, together with their partner, are able to practice one of the specified methods until 4 weeks after the final trial drug administration
  • Patients who are capable of providing written informed consent themselves before any trial-related procedures are performed

Exclusion criteria

Exclusion Criteria:

  • Subjects with a complication of urinary impairment due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
  • Subject with daily urine volume less than 500 mL
  • Subject with Cardiac function of class 4
  • Subjects with serious ischemic heart disease, who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
  • Subjects with serious arrhythmia, who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
  • Subjects who are concomitantly undergoing peritoneal dialysis
  • Subjects with ascites due to cirrhosis or cancer, requring medical treatments
  • Subjects with any of the following medical histories:

    • History of cerebrovascular disorder or coronary artery disease within 4 weeks prior to
    • History of or idiosyncratic reaction to benzazepine derivatives such as mozavaptan hydrochloride or benazepril hydrochloride
  • Subjects with any of the following abnormal laboratory values:

    • lower than 8.0 g/dL, total higher than 3.0 mg/dL, (GPT) or AST (GOT) 2 times the upper limit of the reference range of the trial site, serum sodium higher than the upper limit of the reference range of the trial site, serum sodium lower than 125mEq/L
  • Subjects with serum potassium higher than 6.0mEq/L and abnormal findings inappropriate for inclusion in the trial are observed by 12-lead
  • Subjects who are unable to sense thirst or who have difficulty with fluid or food intake
  • Subjects who have participated in any other clinical trial or post-marketing clinical studies within 4 weeks prior to informed consent
  • Female subjects who are pregnant, possibly pregnant, or nursing, or who plan to become pregnant during the trial period
  • Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    OPC-41061

    Drug: OPC-41061

Interventions

  • The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Daily Urine Volume

    The daily urine volume at each timepoint and its change and the percent change from baseline will be summarized with descriptive statistics (number, mean, standard deviation \[SD\], minimum, median, maximum \[same for following parameters\]).

    Time frame: Baseline and Day 14 (Intermittent Administration Period)

Secondary outcomes

  1. Change From Baseline in Total Fluid Removal Per Week by Dialysis

    The total volume of fluid removed per week by dialysis at each timepoint and its change from baseline will be summarized with descriptive statistics.

    Time frame: Baseline (pretreatment observation period) and Intermittent Administration Period (Day 10 to Day 15)

07

Results

Posted Aug 24, 2018

Participant flow

Participant flow — Overall Study
MilestoneOPC-41061
Started23
Completed16
Not completed7
Withdrew: Lack of efficacy5
Withdrew: Physician decision1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryChange From Baseline in Daily Urine Volume

The daily urine volume at each timepoint and its change and the percent change from baseline will be summarized with descriptive statistics (number, mean, standard deviation \[SD\], minimum, median, maximum \[same for following parameters\]).

Time frame:
Baseline and Day 14 (Intermittent Administration Period)
Reported as:
Mean · ml
Change From Baseline in Daily Urine Volume
mlOPC-41061
Change From Baseline in Daily Urine Volume481.0 ± 427.1
SecondaryChange From Baseline in Total Fluid Removal Per Week by Dialysis

The total volume of fluid removed per week by dialysis at each timepoint and its change from baseline will be summarized with descriptive statistics.

Time frame:
Baseline (pretreatment observation period) and Intermittent Administration Period (Day 10 to Day 15)
Reported as:
Mean · ml
Change From Baseline in Total Fluid Removal Per Week by Dialysis
mlOPC-41061
Change From Baseline in Total Fluid Removal Per Week by Dialysis-1425.0 ± 2139.7

Adverse events

Collected over From the start date of IMP administration to date of the final examination (up to Intermittent Administration Period Day15). Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OPC-410610/23 (0%)0/23 (0%)13/23 (56.5%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventOPC-41061
ThirstGeneral disorders3/23
MalaiseGeneral disorders2/23
NasopharyngitisInfections and infestations2/23
Shunt stenosisInjury, poisoning and procedural complications2/23
HyperkalaemiaMetabolism and nutrition disorders2/23
ArthralgiaMusculoskeletal and connective tissue disorders2/23
PollakiuriaRenal and urinary disorders2/23
Injection site erosionGeneral disorders1/23
PyrexiaGeneral disorders1/23
Vessel puncture site painGeneral disorders1/23

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)OPC-41061
<=18 years0
Between 18 and 65 years11
>=65 years12
Age, Continuous
Age, Continuous(years)OPC-41061
Mean60.4 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)OPC-41061
Female8
Male15
Region of Enrollment
Region of Enrollment(participants)OPC-41061
Japan23
08

Study locations

5 sites
  • Chube Region, Japan
  • Kanto Region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
  • Tohoku Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 4 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2013
First posted
Jun 12, 2013
Start
Jun 2013
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results first posted
Aug 24, 2018
Last update
Aug 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01876381
Responsible party
Sponsor
First posted
Jun 12, 2013
Start date
Jun 2013
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Aug 24, 2018
Last update
Aug 24, 2018

Study contacts

Kyoji Imaoka, Mr
study chair · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion